Percutaneous endoscopic gastrostomy in @entity1 with XXXX .

@entity1 @entity32 @entity2749 @entity706 @entity5 @entity1221 @entity281 @entity1778 @entity970
The objective of the study was to assess both the possible complications of percutaneous endoscopic gastrostomy ( @entity970 ) in @entity5 @entity1 and its effect on weight development. The medical records of 18 @entity1 with a median age of 2.5 years (range, 0.5-14.2 years) were reviewed. The diagnoses were @entity1778 , @entity1221 , @entity5 , and @entity706 . The indications for @entity970 were anticipated therapy-related nutritional problems and inadequate food intake, weight loss, swallowing problems in relation to paresis of the pharynx, and relapse of the disease. Ten @entity1 received a @entity970 at treatment start, and eight @entity1 received it at a median time of 3.4 months (range, 0.9-27.4 months) after treatment start. The median duration of having a @entity970 in place was 12.3 months (range, 1.2-24.0 months). At admission the median weight for age expressed as standard deviation (SD) was -0.11 (range, -2.78-2.68). There was a significant (p =.005) decrease in the median SD from admission until @entity970 installation. There was also a significant increase in the median SD from the start of @entity970 use until 1 (p =.04) and 2 (p =.039) months after start. The most common complications were @entity2749 of @entity32 of the @entity970 site, which were successfully treated with topically or orally administered antibiotics, and @entity2749 of @entity281 , which required intravenously administered antibiotics. Taking into consideration the medical condition of the @entity1 in the study group and the considerable length of time with a @entity970 in place, we believe that nutrition via @entity970 in @entity1 with @entity5 has several advantages and is rarely associated with other than minor complications.
